16th Jan 2014 13:26
LONDON (Alliance News) - Vectura Group PLC said Thursday that its partner Sandoz, part of Novartis AG, has received marketing authorisation for its AirFluSal Forspira inhaler in Hungary.
The authorisation comes after AirFluSal Forspira received marketing authorisation in Germany on Monday, and in Sweden on Tuesday.
The AirFluSal inhaler is designed for the treatment of asthma and chronic obstructive pulmonary disease.
Shares in Vectura were trading up 0.3%, or 0.50 pence, at 158.50 pence Tuesday afternoon.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L